Harpoon Therapeutics (HARP) IPO Opens Flat

Today's IPO for Harpoon Therapeutics (NASDAQ: HARP) opened for trading at $14 after pricing 5,400,000 shares of its common stock at a price to the public of $14.00 per share.

In addition, Harpoon has granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock.

Citigroup and SVB Leerink are acting as joint book-running managers for the offering. Canaccord Genuity and Wedbush PacGrow are acting as co-managers for the offering.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct™ (“TriTAC”), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.

You May Also Be Interested In

• Sinda Ltd. prices IPO at $12 per share on NYSE
• Alopexx files for IPO on NYSE American at $10-$12 per share
• Americore expands private placement to include Quebec investors